Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Neupro
Synonyms :
Rotigotine
Class :
Dopamine Agonists, Antiparkinson Agents
Dosage Forms & Strengths
Adult
Transdermal patch
1 mg
2 mg
3 mg
4 mg
6 mg
8 mg
2
mg/day
transdermal patch
Topical
once a day
for early onset of Parkinson’s disorder
4mg/24hour transdermal patch, one time a day for advanced stage Parkinson's disorder
Note:
A maximum dose of 6mg/24h can be given in case of early-stage and 8mg/24h for advanced-stage
Least effective dose: 4mg/24h
Reduce the dose to 2mg/24h after discontinuation to overcome the effects of withdrawal
Not determined
administration of rotigotine along with amisulpride reduces the activity of each other due to antagonism
Dopamine agonists like rotigotine should not be given with dopamine antagonists like amisulpride
the efficacy of dopamine agonists is decreased with methotrimeprazine when combined
CNS depressants may enhance the sedative effect of rotigotine
CNS depressants may enhance the sedative effect of rotigotine
CNS depressants may enhance the sedative effect of rotigotine
CNS depressants may enhance the sedative effect of rotigotine
CNS depressants may enhance the sedative effect of rotigotine
CNS depressants increase the effect of sedation of rotigotine
CNS depressants increase the effect of sedation of rotigotine
CNS depressants increase the effect of sedation of rotigotine
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
may increase the sedative effect of CNS depressants
The sedative effect of rotigotine might be intensified by the presence of CNS Depressants
The sedative effect of rotigotine might be intensified by the presence of CNS Depressants
The sedative effect of rotigotine might be intensified by the presence of CNS Depressants
acetaminophen/dextromethorphan/pseudoephedrine/guaifenesin
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
brompheniramine, dextromethorphan and phenylephrine
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
the activity of rotigotine may be decreased by loxapine inhaled due to antagonistic effects
the effects of either of the drug may be altered when administered concomitantly
coadministration of rotigotine with olopatadine intranasal solution leads to increase in sedation and CNS depression, causing disturbances in psychomotor performance
calcium, magnesium, potassium and sodium oxybate
may be increased risk of adverse effects such as respiratory distress, sedation, coma or death
CNS depressants increase the effect of rotigotine
CNS depressants increase the effect of rotigotine
CNS depressants increase the effect of sedation of rotigotine
CNS depressants increase the effect of sedation of rotigotine
may decrease the therapeutic effect
may increase the CNS depressant of CNS depressants
may increase the risk or severity of hypertension when combined
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
it may enhance the risk of nephrotoxicity when combined with Diuretics
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
Rotigotine acts as an agonist at all 5 dopamine receptor subtypes, with the highest affinity for the D3 receptor.
It inhibits dopamine uptake and prolactin secretion shows no QT or QTc prolongation effect up in a day.
>10% (Early-stage Parkinson Disease)
Nausea
Dizziness
Somnolence
Vomiting
Fatigue
Insomnia
Hyperhidrosis
1-10% (Early-stage Parkinson Disease)
Abnormal dreams
Dyspepsia
Weight loss
Balance disorder
Erythema
Anorexia
Edema peripheral
Tinnitus
Hiccups
Pruritic rash
Erectile dysfunction
Lethargy
1-10% (Advanced-stage Parkinson Disease)
Vomiting
Headache
Asthenia
Cough
Constipation
Nightmares
Tremor
Erythema
Hyperhidrosis
Musculoskeletal pain
1-10% (Restless Legs Syndrome)
Muscle spasms
Hypertension
Hot flushes
Dyspepsia
Insomnia
Dizziness
Pruritus
Xerostomia
Vertigo
Sinusitis
Abnormal dreams
Constipation
Hyperhidrosis
None
Contraindications:
Hypersensitivity
Cautions:
Cardiovascular Disease
Impulse Control Disorders
Sleep Disorders
Psychiatric Disorders
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology: Rotigotine is a dopamine agonist drug delivered through a skin patch replaced every day to activate dopamine receptors in the body.
Pharmacodynamics: Rotigotine restores dopaminergic activity in the brain to improve motor control in Parkinson’s disease.
Pharmacokinetic:
Absorption:
It reaches peak plasma time in 15 to 18 hours.
Distribution:
It shows protein bound of 92%.
Metabolism:
It is extensively and rapidly metabolized with conjugation and N-dealkylation.
Excretion and elimination:
It is excreted through urine.
It is available in form of transdermal patch.
Patient information leaflet:
Generic Name: Rotigotine
Why do we use Rotigotine?
Rotigotine is indicated in the treatment of Parkinson’s disease including early and advanced stage.
It is used to treat restless legs syndrome.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
